<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
<ArticleSet>
  <Article>
    <Journal>
      <PublisherName>jmedicalcasereports</PublisherName>
      <JournalTitle>Frontiers in Medical Case Reports</JournalTitle>
      <PISSN>I</PISSN>
      <EISSN>S</EISSN>
      <Volume-Issue>Volume 2; Issue 6</Volume-Issue>
      <PartNumber/>
      <IssueTopic>Multidisciplinary</IssueTopic>
      <IssueLanguage>English</IssueLanguage>
      <Season>(Nov-Dec, 2021)</Season>
      <SpecialIssue>N</SpecialIssue>
      <SupplementaryIssue>N</SupplementaryIssue>
      <IssueOA>Y</IssueOA>
      <PubDate>
        <Year>-0001</Year>
        <Month>11</Month>
        <Day>30</Day>
      </PubDate>
      <ArticleType>Medical Case Reports</ArticleType>
      <ArticleTitle>Hepatitis B Virus Reactivation Under Treatment with Ibrutinib, A Known and Still Dangerous Entity: A Clinical Case Description</ArticleTitle>
      <SubTitle/>
      <ArticleLanguage>English</ArticleLanguage>
      <ArticleOA>Y</ArticleOA>
      <FirstPage>1</FirstPage>
      <LastPage>5</LastPage>
      <AuthorList>
        <Author>
          <FirstName>Justine</FirstName>
          <LastName>Adnet</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>N</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Emilie</FirstName>
          <LastName>Reboursiere</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Bertille</FirstName>
          <LastName>Comoz</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Louise</FirstName>
          <LastName>Lebedel</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Charlotte</FirstName>
          <LastName>Orhan</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Astrid</FirstName>
          <LastName>Vabret</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Isabelle</FirstName>
          <LastName>Ollivier-Hourmand</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
          <FirstName>Julia</FirstName>
          <LastName>Dina</LastName>
          <AuthorLanguage>English</AuthorLanguage>
          <Affiliation/>
          <CorrespondingAuthor>Y</CorrespondingAuthor>
          <ORCID/>
        </Author>
      </AuthorList>
      <DOI/>
      <Abstract>During therapies for hematologic malignancies, hepatitis B virus (HBV) reactivation is a frequently reported event. Ibrutinib is a drug prescribed, since a few years, for the treatment of hematologic disease, which inhibit Bruton tyrosin kinase and is metabolized in the liver. Contrary to others molecules, there are no guidelines concerning antiviral systematic prophylaxis against HBV reactivation. Here, we describe a lethal case of hepatitis B reactivation in a patient under Ibrutinib treatment. The purpose of this case report is to emphasize the importance of strict monitoring of serological and molecular markers of hepatitis B in patients treated by Ibrutinib and to draw attention to the delicate interpretation of virological results with the risk of false negative HBsAg detection in the context of a high and brutal increase of the virus replication by hook-effect.</Abstract>
      <AbstractLanguage>English</AbstractLanguage>
      <Keywords>Hepatitis B Virus (HBV),Reactivation,Ibrutinib,Immunosuppressed Patient</Keywords>
      <URLs>
        <Abstract>https://jmedicalcasereports.org/ubijournal-v1copy/journals/abstract.php?article_id=13467&amp;title=Hepatitis B Virus Reactivation Under Treatment with Ibrutinib, A Known and Still Dangerous Entity: A Clinical Case Description</Abstract>
      </URLs>
      <References>
        <ReferencesarticleTitle>References</ReferencesarticleTitle>
        <ReferencesfirstPage>16</ReferencesfirstPage>
        <ReferenceslastPage>19</ReferenceslastPage>
        <References>“EASL 2017 (European Association for The Study of The Liver). Clinical Practice Guidelines on the Management of Hepatitis B Virus Infection.” 2017. J Hepatol 67: 370–398.&#13;
&#13;
“Imbruvica | European Medicines Agency.” n.d.&#13;
&#13;
de Jand;eacute;sus Ngoma P, Kabamba B, Dahlqvist G, Sempoux C, Lanthier N, Shindano T, Van Den Neste E, Horsmans Y. “Occult HBV Reactivation Induced by Ibrutinib Treatment: A Case Report.” Acta Gastroenterol Belg 2015; 78: 424–426.&#13;
&#13;
Hammond SP, Chen K, Pandit A, Davids MS, Issa NC, Marty FM. “Risk of Hepatitis B Virus Reactivation in Patients Treated with Ibrutinib.” Blood. The Journal of the American Society of Hematology 2018; 131: 1987-1989.&#13;
&#13;
Herishanu Y, Katchman H, Polliack A. “Severe Hepatitis B Virus Reactivation Related to Ibrutinib Monotherapy.” Ann Hematol 2017; 96: 689.&#13;
&#13;
Innocenti, Idanna, Francesca Morelli, Francesco Autore, Andrea Corbingi, Raffaella Pasquale, Federica Sorand;agrave;, Maurizio Pompili, and Luca Laurenti. “HBV Reactivation in CLL Patients with Occult HBV Infection Treated with Ibrutinib without Viral Prophylaxis.” Leuk Lymphoma 2019; 60: 1340-1342.&#13;
&#13;
Iskender G, Ertek M. “Hepatitis B Virus Reactivation under Ibrutinib Treatment in a Patient with Chronic Lymphocytic Leukemia.” Turk J Haematol 2020; 37: 208.&#13;
&#13;
Kleijwegt FS, Roda AA, Rolvink J, Kater AP, Kersten MJ, Vos JM. “Rare but Serious: Ibrutinib Induced Liver Failure.” HemaSphere 2019; 3(6).&#13;
&#13;
Pattullo V. “Prevention of Hepatitis B Reactivation in the Setting of Immunosuppression.” Clin Mol Hepatol 2016; 22: 219.&#13;
&#13;
Smalls DJ, Kiger RE, Norris LB, Bennett CL, Love BL. “Hepatitis B Virus Reactivation: Risk Factors and Current Management Strategies.” Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 2019; 39: 1190–1203.&#13;
&#13;
Tedeschi A, Frustaci AM, Mazzucchelli M, Cairoli R, Montillo M. “Is HBV Prophylaxis Required during CLL Treatment with Ibrutinib?” Leuk Lymphoma 2017; 58: 2966-2968.&#13;
&#13;
Tsuruya K, Anzai K, Shioyama S, Ito A, Arase Y, Hirose S, Tanaka Y, Suzuki H, Kagawa T. “Case of Hepatitis B Virus Reactivation after Ibrutinib Therapy in Which the Patient Remained Negative for Hepatitis B Surface Antigens throughout the Clinical Course.” Hepatol Res 2021; 51: 239–244.&#13;
&#13;
Yang R, Cui L, Liu Y, Cong X, Fei R, Wu S, Wei L. “A Hook-Effect-Free Homogeneous Light-Initiated Chemiluminescence Assay: Is It Reliable for Screening and the Quantification of the Hepatitis B Surface Antigen?” Ann Transl Med 2020; 8: 606–606.</References>
      </References>
    </Journal>
  </Article>
</ArticleSet>